Abbott boasts of heart failure reduction data for CardioMEMS device

• Abbott Laboratories said that a new study found that the company's pulmonary artery pressure monitoring device CardioMEMS led to a 44% reduction in heart failure-related hospitalizations among chronic heart failure patients.
• Also, improvement in quality-of-life scores was observed as soon as three months after use with the remote monitoring sensor.
• The prospective, randomized study known as MONITOR-HF examined ~350 patients in the Netherlands. Individuals were monitored for a year and complication risk was only 2.3%, which is consistent with previous investigations.
• CardioMEMS was approved by the US FDA in 2014 and received the European Conformity ("CE") mark in 2016.

More on Abbott

• Abbott Laboratories: A Mixed, Yet Expensive Bag

• Abbott Remains A Top Pick For Dividend Investors